These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 39208834)

  • 1. Nirsevimab-a breakthrough in respiratory syncytial virus bronchiolitis.
    Assad Z; Papenburg J; Ouldali N
    Lancet Child Adolesc Health; 2024 Oct; 8(10):708-709. PubMed ID: 39208834
    [No Abstract]   [Full Text] [Related]  

  • 2. Nirsevimab Effectiveness Against Cases of Respiratory Syncytial Virus Bronchiolitis Hospitalised in Paediatric Intensive Care Units in France, September 2023-January 2024.
    Paireau J; Durand C; Raimbault S; Cazaubon J; Mortamet G; Viriot D; Milesi C; Daudens-Vaysse E; Ploin D; Tessier S; Vanel N; Chappert JL; Levieux K; Ollivier R; Daoudi J; Coignard B; Leteurtre S; Parent-du-Châtelet I; Vaux S
    Influenza Other Respir Viruses; 2024 Jun; 18(6):e13311. PubMed ID: 38840301
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of nirsevimab on hospitalisations for respiratory syncytial virus bronchiolitis in France, 2023-24: a modelling study.
    Brault A; Pontais I; Enouf V; Debeuret C; Bloch E; Paireau J; Rameix-Welti MA; White M; Baudemont G; Lina B; Parent du Châtelet I; Casalegno JS; Vaux S; Cauchemez S
    Lancet Child Adolesc Health; 2024 Oct; 8(10):721-729. PubMed ID: 39208833
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High rate of indigenous bronchiolitis and palivuzumab.
    Whitehall JS; Bolisetty S; Whitehall JP; Francis F; Norton R; Patole SK
    J Paediatr Child Health; 2001 Aug; 37(4):416-7. PubMed ID: 11547779
    [No Abstract]   [Full Text] [Related]  

  • 5. Nirsevimab and Hospitalization for RSV Bronchiolitis.
    Assad Z; Romain AS; Aupiais C; Shum M; Schrimpf C; Lorrot M; Corvol H; Prevost B; Ferrandiz C; Giolito A; Valtuille Z; Bendavid M; Cohen JF; Toubiana J; de Pontual L; Delande CF; Levy M; See P; Cohen R; Levy C; Angoulvant F; Lenglart L; Gits-Muselli M; Biran V; Diallo K; Alemede O; El Hebil MM; Durrmeyer X; Labouret G; Casanovas N; Hallak B; Maréchal O; Jung C; Bréhin C; Ouldali N
    N Engl J Med; 2024 Jul; 391(2):144-154. PubMed ID: 38986058
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY).
    Tuffy KM; Ahani B; Domachowske JB; Furuno K; Ji H; Madhi SA; Mankad VS; Hamrén UW; Villafana T; Wang Y; Kelly EJ; Wilkins D
    Vaccine; 2024 Oct; 42(24):126276. PubMed ID: 39241352
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Palivizumab and bronchiolitis: need to apply the efficiency in order to join clinical practice to scientific studies].
    González de Dios J; Ochoa Sangrador C
    Med Clin (Barc); 2005 Apr; 124(12):478-9. PubMed ID: 15826590
    [No Abstract]   [Full Text] [Related]  

  • 8. Nirsevimab Immunization to Prevent Respiratory Syncytial Virus-Associated Lower Respiratory Tract Infections in Infants and Children up to 24 Months of Age.
    Cieslak CM
    Nurs Womens Health; 2024 Feb; 28(1):75-79. PubMed ID: 38070539
    [TBL] [Abstract][Full Text] [Related]  

  • 9. RSVpreF (Abrysvo) and Nirsevimab-alip (Beyfortus) for the Prevention of Respiratory Syncytial Virus Infection.
    Nodelman M; Scott AM
    Am Fam Physician; 2024 Jun; 109(6):578-579. PubMed ID: 38905561
    [No Abstract]   [Full Text] [Related]  

  • 10. Nirsevimab and Acute Bronchiolitis Episodes in Pediatric Emergency Departments.
    Andina Martínez D; Claret Teruel G; Gijón Mediavilla M; Cámara Otegui A; Baños López L; de Miguel Lavisier B; Ferrero García-Loygorri C; Sánchez Tatay V; Pavlovic Nesic S; Clerigué Arrieta N; Gimeno-Hernández Garza V; Guerra Diez JL; Ranera Málaga A; Escalada Pellitero S; Barrueco Ramos C; Alonso-Cadenas JA;
    Pediatrics; 2024 Oct; 154(4):. PubMed ID: 39257372
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Recommendations for palivizumab use. Update 2015].
    ; Fernández Jonusas S; Albas Maubett D; Satragno D; Cattaino A; Martin Alonso M; Rubio C; Nieto R; ; ; ; ; ; ;
    Arch Argent Pediatr; 2016 Feb; 114(1):84-8. PubMed ID: 26914078
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nirsevimab for the prevention of respiratory syncytial virus disease in children. Statement of the Spanish Society of Paediatric Infectious Disease (SEIP).
    Francisco L; Cruz-Cañete M; Pérez C; Couceiro JA; Otheo E; Launes C; Rodrigo C; Jiménez AB; Llorente M; Montesdeoca A; Rumbao J; Calvo C; Frago S; Tagarro A
    An Pediatr (Engl Ed); 2023 Oct; 99(4):257-263. PubMed ID: 37743207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nirsevimab to reduce infant morbidity from respiratory syncytial virus.
    Abu-Raya B; Langley JM; Lavoie P
    CMAJ; 2024 Sep; 196(32):E1114-E1117. PubMed ID: 39353638
    [No Abstract]   [Full Text] [Related]  

  • 14. CDC changes recommendations due to severe nirsevimab shortage during the 2023-2024 RSV season.
    Rahmat ZS; Ahmad S; Malikzai A
    Pediatr Pulmonol; 2024 Apr; 59(4):1108-1109. PubMed ID: 38240360
    [No Abstract]   [Full Text] [Related]  

  • 15. Respiratory syncytial virus immune globulin: decisions and costs.
    Barton LL; Grant KL; Lemen RJ
    Pediatr Pulmonol; 2001 Jul; 32(1):20-8. PubMed ID: 11416872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Management of respiratory syncytial virus infection.
    Kimpen JL
    Curr Opin Infect Dis; 2001 Jun; 14(3):323-8. PubMed ID: 11964851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Timing of bronchiolitis hospitalisations and respiratory syncytial virus immunoprophylaxis in non-metropolitan Western Australia.
    Moore HC; Keil AD; Richmond PC; Lehmann D
    Med J Aust; 2009 Nov; 191(10):574. PubMed ID: 19912095
    [No Abstract]   [Full Text] [Related]  

  • 18. Palivizumab for immunoprophylaxis of respiratory syncytial virus (RSV) bronchiolitis in high-risk infants and young children: a systematic review and additional economic modelling of subgroup analyses.
    Wang D; Bayliss S; Meads C
    Health Technol Assess; 2011 Jan; 15(5):iii-iv, 1-124. PubMed ID: 21281564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
    Lewis L; Sinha I; Losty PD
    Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Prevention of respiratory syncytial virus bronchiolitis].
    Marchac V
    Arch Pediatr; 2006 Dec; 13 Suppl 5():S12-7. PubMed ID: 17550819
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.